Mouse Models For Human Prostate Cancer: Xenograft Vs Genetically Engineered Mouse Model
Prostate cancer is among the commonest cancers in men with high mortality. It is thought to arise from accumulated genetic mutations that may transform benign prostatic epithelium to prostatic intraepithelial neoplasia (PIN). With additional genetic alterations, PIN progresses to invasive cancer, and finally to metastatic disease. Metastatic prostate cancer is generally accompanied by emergence of androgen-independent cancer. About 70% of primary prostate cancers exhibit a loss of at least one PTEN allele and loss of both alleles is associated with advanced disease. PTEN is tumor suppressor gene that works by suppressing the activity of Akt /PKB pathway. Over expression of many oncogenes has also been observed in many human prostate cancers. Animal models are crucial to understand the underlying biology and to test novel prevention and treatment strategies for prostate cancer. Appropriate animal models should recapitulate genetic alterations and clinical courses of human prostate cancer.
The following paper describes important characteristics of genetically modified mouse model and xenograft mouse model. We performed recent literature search for human prostate cancer mouse models.
Numerous mouse models of human prostate cancer have been generated and exhibit common characteristics of human prostate cancer. Initially, the immunocompromised mouse was used as a xenograft model for in vivo analyses of human prostate cell lines. This approach does not however consider the heterogonous nature of prostate cancer as a disease with complex interactions between the transformed cells, the resident cells, the stromal cells, the endothelial cells and the immune cells all which participate in the disease pathogenesis. One of the genetically engineered mouse models is the prostate specific Cre-mediated conditional expression of Myc oncogene by removal of a conditional STOP sequence (PB-c-Myc,).This model progresses to invasive carcinoma without metastasis. The other is a conditional PTEN Knockout model using Cre recombinase targeted to the prostate specific probasin promoter. This model recapitulates the human prostate cancer to metastasis carcinoma.
Genetically engineered mouse models are more able to recapitulate the human prostate cancer compare to the xenograft. The PTEN knock out mouse is suitable for understanding molecular basis of the disease. Xenograft will remain more useful testing of therapy. In the future more sophisticated prostate animal model should be available so as to recapitulate the heterogeneity of the disease
Keywords: Knockout, Mouse model, Oncogene, prostate cancer, Xenograft
Pienta KJ etal., The Current State of Preclinical Prostate Cancer Animal Models, The Prostate, 2008; 68:629- 639
Lamb DJ and Zhang L, Challenges in Prostate Cancer Research: Animal Models for Nutritional Studies of Chemoprevention and Disease Progression J. Nutr, 2005; 135
Ittmann M etal, Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee, Cancer Res,2013; 73(9)
Winter SF, Cooper AB & Greenberg NM, Models of metastatic prostate cancer: a transgenic perspective, Prostate Cancer and Prostatic Diseases (2003) 6, 204–211
Sharma P and Schreiber-Agus N, Mouse models of prostate cancer, Oncogene (1999) 18, 5349 ± 5355
Nawijn MC etal, Genetically Engineered Mouse Models of Prostate Cancer, european urology supplements ( 2 0 0 8 ) 7, 566–575
Gaupel AC etal, Animals Models of Prostate Cancer, Animal model for the study of human disease, Department of Biomedical Sciences, School of Public Health and Cancer Research Center, University at Albany, Rensselaer, NY, USA chapter 39 , 2013; pp973-995
Wang S etal, Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer, CANCER CELL : SEPTEMBER 2003 • VOL. 4 209-221
Tsugawa K etal, BIOLOGICAL ROLE OF PHOSPHATASE PTEN IN CANCER AND TISSUE INJURY HEALING, Frontiers in Bioscience 7, 2002; e245-251
Trotman LC etal , Pten dose dictates cancer progression in the prostate, PLoS Biol. 2003 Dec;1(3):E59
Richmond A and Su1 Y, Mouse xenograft models vs GEM models for human cancer therapeutics, Dis Model Mech. 2008 Sep-Oct; 1(2-3): 78–82.